Sens. Shelley Moore Capito (R-WV) and Jon Tester (D-MT) have introduced Senate bill S. 413, legislation that would prohibit pharmacy direct and indirect remuneration (DIR) fees from being applied after the point-of-sale for prescription drugs dispensed to Medicare beneficiaries. The legislation is a companion bill to H.R. 1038, introduced in the House of Representatives earlier this week. NCPA CEO B. Douglas Hoey says the legislation would "address a top concern for independent community pharmacy owners: huge monetary clawbacks assessed by Medicare drug plans, or their intermediaries, PBM corporations, long after prescriptions are filled and the pharmacy paid. These fees are often labeled direct and indirect remuneration, or pharmacy DIR fees. Like its House companion bill, H.R. 1038, S. 413 would prohibit the imposition of such fees after pharmacies fill prescriptions and are reimbursed in Medicare Part D."